Oracle Corp (NYSE:ORCL, XETRA:ORC) shares moved more than 7% higher after the company reported stronger-than-expected earnings for its fiscal third quarter and raised its longer-term revenue outlook.
The enterprise software company posted non-GAAP earnings per share of $1.79, topping Wall Street estimates of $1.69. Revenue came in at $17.2 billion, roughly in line with analyst expectations.
Bank of America analysts have lowered their price target on Paramount Skydance Corp (NASDAQ:PSKY) while reiterating an ‘Underperform’ rating, pointing to near-term uncertainty surrounding the company’s planned acquisition of Warner Bros. Discovery Inc (NASDAQ:WBD, XETRA:J5A).
In a note on Tuesday, the bank reduced its price objective on Paramount Skydance to $11 from $13. Shares traded almost 8% lower at about $10 on Tuesday afternoon.
NIO Inc (NYSE:NIO), a Chinese manufacturer of smart electric vehicles, saw its US-listed shares surge almost 10% after it reported its first-ever net profit in the fourth quarter of 2025, driven by record vehicle deliveries and improved margins.
The company, considered one of the top three emerging EV brands in China alongside XPeng and Li Auto, delivered 124,807 vehicles in the quarter, a 71.7% increase from the fourth quarter of 2024 and a 43.3% rise from the third quarter of 2025. December deliveries reached a record 48,135 units.
BioNTech SE (NASDAQ:BNTX) co-founders Ugur Sahin and Özlem Türeci plan to launch a new independent biotech company focused on next-generation mRNA technologies, the German vaccine developer said on Tuesday, as it intensifies its focus on oncology.
BioNTech said it will contribute certain related rights and technologies to the new venture in exchange for a minority stake, with potential milestone payments and royalties.
374Water Inc (NASDAQ:SCWO, FRA:8LL) announced that it has received approval from the City of Orlando to provide waste destruction services at the Iron Bridge Regional Water Reclamation Facility, marking a step toward expanding the company’s commercial operations for the treatment of organic waste streams.
The cleantech company said the approval grants it a license to operate its Waste Destruction Services platform at the facility for an initial five-year term, with options for two additional five-year extensions.
Nextech3D.AI (CSE:NTAR, OTCQX:NEXCF, FRA:1SS) announced hat it has signed 50 new customer contracts since the start of 2026, representing approximately $230,000 in total contracted value, as adoption of its artificial intelligence-powered event technology platform continues to grow.
The company said the contracts were secured between January and early March and reflect agreements with first-time customers. The figure excludes renewals and expansion revenue from existing clients, which the company noted remains a separate component of its overall revenue.
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) highlighted progress across its clinical pipeline and reaffirmed its financial outlook during its 2026 Virtual Investor Day, outlining plans to advance its lead candidate BPL-003 into Phase 3 trials for treatment-resistant depression while continuing development of additional mental health therapies.
The clinical-stage biotechnology company said it remains on track to initiate two parallel Phase 3 pivotal studies of BPL-003, a mebufotenin benzoate nasal spray, in the second quarter of 2026 following a successful End-of-Phase 2 meeting with the US Food and Drug Administration. The drug candidate has received Breakthrough Therapy Designation and is being developed as a rapid-acting treatment for patients with treatment-resistant depression.
Shares in Pennon Group PLC (LSE:PNN, OTC:PEGRY) rose 3.4% to 553.5p on Tueaday morning despite the owner of South West Water saying full-year profitability would come in at the lower end of market expectations.
The FTSE 250 water company said exceptional rainfall and storm-related disruption have pushed up costs.
AIM modelling company raises £450,000 at a steep discount, betting that investment in growth will justify near-term pain for shareholders
Shares in Physiomics, the AIM-listed mathematical modelling and data science company serving the pharmaceutical industry, fell 27% to 0.33p after it announced a placing at 0.3p per share, a discount of approximately 33% to the previous closing price, leaving the company valued at less than £1 million.